DITTO Daily develops a flagship Cycle Supplement that uses beadlet-in-oil time-release technology to deliver 10 clinically supported ingredients aimed at reducing PMS and PMDD symptoms. In a clinical trial cited by the company, 88% of participants reported reduced symptom severity. The company emphasizes translating academic research into accessible guidance and has grown a community to 300,000 members in 18 months. Founded in 2024, DITTO’s team has expanded to 15 employees and includes medical advisors such as a gynaecologist and a women’s health GP. The funding will support expansion of the supplement and further clinical research, including trials investigating a potential overlap between PMDD and ADHD and plans to conduct three additional trials and publish five papers over the next year.

Total raised

$8M

Funding rounds

2

Latest round

Seed

Latest activity

Jul 2026